FVIII tolerance in the Emicizumab era: Why yes?

Abstract

when estimating the risk of inhibitor development 3 and more than 70% of mutations responsible for severe forms of HA are associated with a high risk of developing it. 2 This fact is supported by other subsequent observations such as that of Jonker et al. 4 which cite 3 factors especially associated with the risk of inhibitor development: a positive family history of inhibitors, a high-risk F8 genotype, and intensive treatment at first exposure.